US EditionPublished • loading... • Updated
BioMarin’s Presence in Rare Enzyme Disorders Grows With $4.8B Amicus Therapeutics Acquisition
The $4.8 billion all-cash acquisition adds two marketed rare disease therapies with $599 million in revenue over four quarters and is expected to boost BioMarin's earnings per share.
- In a press release from San Rafael, Calif., Amicus Therapeutics announced it entered a definitive agreement to acquire BioMarin Pharmaceutical Inc. for $14.50 per share, with a conference call at 8:15 a.m. ET.
- The acquisition adds Galafold and Pombiliti + Opfolda to BioMarin's rare-disease portfolio, generating $599 million over the past four quarters and expected to accelerate revenue growth.
- Under the terms of the agreement, BioMarin will finance the deal with cash and approximately $3.7 billion of non‑convertible debt, with Morgan Stanley Senior Funding, Inc. as sole lead arranger and bridge commitment.
- The boards unanimously approved the agreement and Amicus stockholders must adopt it; closing is expected in the second quarter of 2026 after satisfying customary conditions.
- Pending patent settlements establish U.S. exclusivity for Galafold 123 mg capsules through January 30, 2037, while BioMarin targets gross leverage <2.5x within two years after closing.
Insights by Ground AI
Podcasts & Opinions
14 Articles
14 Articles
BioMarin’s Presence in Rare Enzyme Disorders Grows With $4.8B Amicus Therapeutics Acquisition
BioMarin Pharmaceutical’s acquisition of Amicus Therapeutics is a marriage of two rare disease biotech companies. Amicus’s two commercialized products, for the enzyme deficiencies Fabry disease and Pompe disease, are each projected to become blockbuster sellers. The post BioMarin’s Presence in Rare Enzyme Disorders Grows With $4.8B Amicus Therapeutics Acquisition appeared first on MedCity News.
BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook
BioMarin to Gain Galafold® (migalastat) for Fabry Disease and Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) for Pompe Disease, Adding Two...
·United States
Read Full ArticleCoverage Details
Total News Sources14
Leaning Left2Leaning Right0Center4Last UpdatedBias Distribution67% Center
Bias Distribution
- 67% of the sources are Center
67% Center
L 33%
C 67%
Factuality
To view factuality data please Upgrade to Premium
